Citigroup Reiterates “Sell” Rating for Novonesis A/S (OTC:NVZMY)

Citigroup reaffirmed their sell rating on shares of Novonesis A/S (OTC:NVZMY) in a report issued on Thursday, StockNewsAPI reports.

Novonesis A/S Stock Performance

Shares of NVZMY opened at $65.72 on Thursday. Novonesis A/S has a fifty-two week low of $38.83 and a fifty-two week high of $72.50. The stock has a market capitalization of $30.78 billion, a price-to-earnings ratio of 41.59, a price-to-earnings-growth ratio of 3.86 and a beta of 0.89.

Novonesis A/S Company Profile

Novonesis A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.